Skip to main content
Signal8

Mentari Therapeutics, Inc. (MTRI)

Industry: Biotechnology

Mentari Therapeutics, Inc. logo

Mentari Therapeutics, Inc.

NASDAQ:MTRIHealthcare
-11.93%$17.50
CLOSED
AH$17.50+0.00%vs close
Mkt Cap$924.24M
EV-
Float35.49M
O/S52.81M
VOL171K sh
$ Vol$3.08M
RVOL5.22×
Inst Own-
SI<0.1%
Net Cash/Sh-
EarningsFeb 10 · in 3mo
Dilution
Mentari Therapeutics, Inc. logoNASDAQ:MTRIClosed$17.50-11.93%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 202619.2720.0016.9317.50171,052
Nov 16, 202617.7219.8717.7219.8711,681
Nov 13, 202619.0220.0018.4018.6011,958
Nov 12, 202615.7519.1714.7618.35145,626
Nov 11, 202612.5016.5012.5015.6160,107
Nov 10, 202614.3515.8412.2012.2057,481
Nov 9, 202614.8016.9512.3416.0054,288
Nov 6, 202613.7116.4413.7015.5627,155
Nov 5, 202614.0015.4912.8813.2132,864
Nov 4, 202618.0018.3016.2017.5012,062
Nov 3, 202615.3017.7015.1016.8017,483
Nov 2, 202615.9516.5014.8516.3014,055
Oct 30, 202615.5016.1015.1016.003,668
Oct 29, 202615.9016.4015.9016.253,740
Oct 28, 202616.3016.7015.9015.994,321
Oct 27, 202615.9016.8015.4015.9011,478
Oct 26, 202614.4016.2114.1015.9029,439
Oct 23, 202613.2115.4013.2014.4012,592
Oct 22, 202613.6013.7513.3013.30829
Oct 21, 202613.2013.9013.2013.602,719
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$30.00+71.4%
Low $30High $30
Ratings Distribution
BUY
2
HOLD
0
SELL
0
TOTAL2
Insider Trades
InsiderTypeShares
Pernice Michelle Patricia profile photoPernice Michelle PatriciaGrant/Award37.0K
Bruno Julianne profile photoBruno JulianneGrant/Award37.0K
Divis Gregory J profile photoDivis Gregory JGrant/Award1.56M
Hagen Brett R profile photoHagen Brett RGrant/Award171.0K
Sandler Laura Lee profile photoSandler Laura LeeGrant/Award37.0K
Seurer Jerad G. profile photoSeurer Jerad G.Grant/Award257.0K
Shareholders
Insiders & Institutional Holders
About

InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids.

Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief.

Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research.

It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently.

The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada.

It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.

Key Metrics
Market Cap$924.24M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 52.81M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
CountryCACA
IPO DateMay 5, 2014
Shares Outstanding52.81M
Authorized Shares
Float35.49M
52-Week Range
$5.75$23.30
$17.50(67th percentile)
Volume
Average Daily Volume32.78K
171.05K today vs 32.78K avg(+422%)

30d Avg

32.78K

60d Avg

18.58K

90d Avg

15.03K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of MTRI as of Sep 30, 2026 records an effective S-3 shelf registration (effective Mar 30, 2026), an at-the-market sales agreement dated Apr 7, 2022 and 3 outstanding warrant series, from SEC filings. 1 insider reported 16 open-market purchases of MTRI stock on Form 4 in the 90 days to Nov 18, 2026. Mentari Therapeutics, Inc. (NASDAQ: MTRI) traded at $17.50 on Nov 17, 2026, down 11.93% from the previous close of $19.87. 52-week range: $5.75 to $23.30. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).